Whereas tetrahydrofolate is an essential cofactor in all bacteria, the gene that encodes the enzyme dihydrofolate reductase (DHFR) could not be identified in many of the bacteria whose genomes have been entirely sequenced. In this communication we show that the halophilic archaea Halobacterium salinarum and Haloarcula marismortui contain genes coding for proteins with an N-terminal domain homologous to dihydrofolate synthase (FolC) and a C-terminal domain homologous to dihydropteroate synthase (FolP). These genes are able to complement a Haloferax volcanii mutant that lacks DHFR. We also show that the Helicobacter pylori dihydropteroate synthase can complement an Escherichia coli mutant that lacks DHFR. Activity resides in an N-terminal segment that is homologous to the polypeptide linker that connects the dihydrofolate synthase and dihydropteroate synthase domains in the haloarchaeal enzymes. The purified recombinant H. pylori dihydropteroate synthase was found to be a flavoprotein.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1365-2958.2004.04339.x | DOI Listing |
Infect Drug Resist
December 2024
Beijing Institute of Tropical Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.
Purpose: pneumonia (PJP) shows a high fatality rate in non-HIV patients. However, there are limited data on drug resistance-related gene mutations in these patients. This study aimed to describe the prevalence of mutations in the dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) genes of in non-HIV patients in China, providing a reference for drug usage.
View Article and Find Full Text PDFIET Syst Biol
December 2024
Institute of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
Klebsiella pneumoniae, an opportunistic pathogen, is pervasively distributed across the world. Its escalating antibiotic resistance poses a serious threat to global public health. The mechanisms behind this resistance remain largely elusive.
View Article and Find Full Text PDFWellcome Open Res
June 2024
MARCAD Program, The biotechnology Centre, University of Yaounde I, Yaounde, Centre, P 0 Box 8094, Cameroon.
Background: Antimalarial drug resistance is a major challenge in the fight against malaria. Cameroon implemented seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine (SPAQ) to over 1.5 million children aged 3-59 months from 2016, raising concerns whether drug pressure may lead to a selection of known parasite resistance mutations.
View Article and Find Full Text PDFJ Glob Antimicrob Resist
November 2024
Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Laboratorio de Resistencia Bacteriana, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
Sci Rep
November 2024
Department of Parasite Disease Control and Prevention, Henan Provincial Key Laboratory of Pathogenic Microbiology, Henan Provincial Medical Key Laboratory of Parasitic Diseases and Vector, Henan Province Center for Disease Control and Prevention, Zhengzhou, People's Republic of China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!